Investing.com - Rallybio reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Rallybio announced earnings per share of $-0.60 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.50 on revenue of $0.00.
Rallybio shares are down 32% from the beginning of the year , still down 58.95% from its 52 week high of $21.00 set on Wednesday, November 10, 2021.
Rallybio follows other major Healthcare sector earnings this month
Rallybio's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar